Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing

Hepatology

Volumn 62, Issue 2, 2015, Pages 340-342

  Romagnoli, Renato ^a   Mazzaferro, Vincenzo ^b   Bruix, Jordi ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN;

ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURGERY; CHILD PUGH SCORE; COHORT ANALYSIS; DATA BASE; EDITORIAL; GENERAL CONDITION DETERIORATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MODEL FOR END STAGE LIVER DISEASE SCORE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK FACTOR; SURGICAL MORTALITY; SURVIVAL RATE; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; MORTALITY; PATIENT SELECTION; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; PATIENT SELECTION;

EID: 84938204638     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27831     Document Type: Editorial

References (9)

1. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
3. Capussotti L, Ferrero A, Viganò L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992-999.
4. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009;250:922-928.
5. Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015;62:440-451.
6. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008;134:1908-1916.
7. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 2015;61:526-536.
8. Choi SB, Kim HJ, Song TJ, Ahn HS, Choi SY. Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 2014;21:639-647.
9. Tang YH, Zhu WJ, Wen TF. Influence of clinically significant portal hypertension on hepatectomy for hepatocellular cancer: a meta-analysis. Asian Pac J Cancer Prev 2014;15:1649-1654.